In vitro stimulation of warfarin metabolism by quinidine: Increases in the formation of 4′- and 10-hydroxywarfarin

Drug Metabolism and Disposition

Volumn 29, Issue 6, 2001, Pages 877-886

  Ngui, Jason S ^a   Chen, Qing ^a   Shou, Magang ^a   Wang, Regina W ^a   Stearns, Ralph A ^a   Baillie, Thomas A ^a   Tang, Wei ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYWARFARIN; 4' HYDROXYWARFARIN; QUINIDINE; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BINDING SITE; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; MALE; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HEPATOCYTES; HUMANS; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; QUINIDINE; RECOMBINANT PROTEINS; WARFARIN;

EID: 0035015062     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE and Trager WF (1996) Wartarin-fluconazole II: a metabolically based drug interaction: in vivo studies. Drug Metab Dispos 24:422-428.
2. Bowles SK, Reeves RA, Cardozo L and Edwards DJ (1993) Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. J Clin Pharmacol 33: 727-731.
3. Buening MK, Chang RL, Huang M-T, Fortner JG, Wood AW and Conney AH (1981) Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 41:67-72.
4. Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19:317-366.
5. Domanski TL, He Y-A, Harlow GR and Halpert JR (2000) Dual role of human cytochrome P450 3A4 residue PHE 304 in substrate specificity and cooperjtivity. J Pharmacol Exp Ther 293:585-591.
6. Ekins S, Bravi G, Wikel JH and Wrighton SA (1999) Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther 291:424-433.
7. Fihn SD (1995) Aiming for safe anticoagulation. N Eng J Med 333:54-55.
8. Grace AA and Camm AJ (1998) Quimdine. N Engl J Med 338:35-44.
9. Guengerich FP (1997) Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 43:7-35.
10. Guengerich FP, Muller-Enoch D and Blair IA (1986) Oxidation of quinidine by human liver cytochrome P450. Mol Pharmacol 30:287-295.
11. Guentert TW, Daly JJ and Riegelman S (1982) Isolation, characterization and synthesis of a new quinidine metabolite. Eur J Drug Metab Pharmacokinet 7:31-38.
12. Harder S and Thurmann P (1996) Clinical important drug interactions with anticoagulants. Clin Pharmacokinet 30:416-444.
13. Harlow GR and Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci USA 95:6636-6641.
14. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA and Goulart DA (1987) The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 42:388-394.
15. Hosea NA, Miller GP and Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
16. Kaminsky LS and Zhang Z-Y (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74.
17. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ and Levy RH (1994) Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47:1969-1979.
18. Koch-Weser J (1968) Quinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy. Ann Intern Med 68:511-517.
19. Koch-Weser J and Sellers EM (1971) Drug interactions with coumarin anticoagulants. N Eng J Med 285:547-558.
20. Koley AP, Buters JTM, Robinson RC, Markowitz A and Friedman FK (1995) CO binding kinetics of human cytochrome P450 3A4. J Biol Chem 270:5014-5018.
21. Koley AP, Buters JTM, Robinson RC, Markowitz A and Friedman FK (1997) Differential mechanism of cytochrome P450 inhibition and activation by α-naphthoflavone. J Biol Chem 272:3149-3152.
22. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
23. Kunze K, Eddy AC, Gibaldi M and Trager WF (1991) Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 3:24-29.
24. Lasker JM, Huang M-T and Conney AH (1982) In vivo activation of zoxazolamine metabolism by flaxone. Science (Wash DC) 216:1419-1421.
25. Ludwig E, Schmid J, Beschke K and Ebner T (1999) Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther 290:1-8.
26. Marquardt DW (1963) An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math 11:431-441.
27. Mei Q, Tang C, Assang C, Slaughter D, Rodrigues DA, Rushmore TH and Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749-759.
28. Ngui JS, Tang W, Steams RA, Shou M, Miller RR, Zhang Y, Lin JH and Baillie TA (2000) Cytochrome P450 3A4-mediated interactions of diclofenac and quinidine. Dug Metab Dispos 28:1043-1050.
29. O'Reilly RA (1975) Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 83:506-508.
30. O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC and Trager WF (1992) Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 51:656-667.
31. Pang J-M, Zaleski J and Kauffman FC (1997) Toxicity of allyl alcohol in primary cultures of freshly isolated and cryopreserved hepatocytes maintained on hydrated collagen gels. Toxicol Appl Pharmacol 142:87-94.
32. Raucy JL and Lasker JM (1991) Isolation of P450 enzymes from human liver. Methods Enzymol 206:557-587.
33. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
34. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV and Shou M (2000) Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochrome P450. Xenobiotica 30:327-343.
35. Schellens JH, Ghabrial H, van der Wart HH, Bakker EN, Wikinson GR and Breimer DD (1991) Differential effects of quinidine on the disposition of nifedipine, sparteine and mephenytoin in humans. Clin Pharmacol Ther 50:520-528.
36. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV and Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
37. Sylven C and Anderson P (1983) Evidence that disopyramide does not interact with warfarin. Br Med J 286:1181-1182.
38. Szklarz GD and Halpert JR (1997) Molecular modeling of cytochrome P450 3A4. J Comput Aided Mol Design 11:265-272.
39. Szklarz GD and Halpert JR (1998) Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab Dispos 26:1379-1184.
40. Tang W, Steams RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999) Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
41. Trenk D, Mohrke W, Warth L and Jahnchen E (1993) Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. Arzneim-Forsch 43:836-841.
42. Ueng Y-F, Kuwabara T, Chun Y-J and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 35:370-381.
43. Wells PS, Holbrook AM, Crowther NR and Hirsh J (1994) Interactions of warfarin with drugs and food. Ann Intern Med 121:676-683.
44. Wrighton SA and Stevens JC (1992) The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
45. Yamazaki H and Shimada T (1997) Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers. Biochem Pharmacol 54:1195-1203.